Want to see VIR full AI Analyst Report?
VIR Stock Chart & Stats
$11.08
$0.21(2.47%)
At close: 4:00 PM EDT
$11.08
$0.21(2.47%)
Day’s Range― - ―
52-Week Range$4.82 - $12.00
Previous CloseN/A
Volume776.97K
Average Volume (3M)2.14M
Market Cap
$1.82B
Enterprise Value$1.28B
Total Cash (Recent Filing)$528.59M
Total Debt (Recent Filing)$93.27M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 04, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding169,215,960
10 Day Avg. Volume2,004,167
30 Day Avg. Volume2,144,084
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue4.22
Enterprise Value/Gross Profit4.39
Enterprise Value/Ebitda-4.77
Forecast
1Y Price Target
$21.29Price Target Upside92.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$245.24M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And RunwayA cash balance of approximately $1.01 billion and projected runway into the second half of 2028 provide meaningful funding for clinical development and commercial preparation. This reduces near-term financing pressure and gives Vir flexibility to advance multiple programs through important milestones.
Durable Hepatitis Clinical DifferentiationThe Week 96 efficacy difference supports potentially durable viral clearance and meaningful differentiation for Vir’s hepatitis program. Completed Phase III enrollment further converts the clinical opportunity into defined regulatory milestones, strengthening the company’s medium-term development position.
Strategic Oncology ValidationThe Gilead collaboration externally validates Vir’s PRO-XTEN platform and gives the company access to a partner with later-stage development and commercialization capabilities. Exclusive licensing of three candidates can broaden Vir’s oncology pipeline while sharing downstream execution responsibilities.
Bears Say
Persistent Operating Losses And Cash BurnSustained negative operating and free cash flow shows that Vir continues to consume cash to fund operations despite its strong balance sheet. If losses persist, ongoing development spending will reduce financial flexibility and could increase reliance on partnerships or future external financing.
Profitability Depends On Collaboration RevenueNear-term profitability is not yet supported by recurring commercial revenue, because the latest positive quarter was primarily driven by collaboration recognition. This makes reported earnings volatile and leaves future results dependent on milestone, upfront, and other partnership payments.
Limited HDV Diagnosis Constrains UptakeLow current diagnosis rates could limit the addressable treated population even if Vir’s hepatitis therapy reaches the market successfully. Expansion will require greater awareness and reflex testing, creating uncertainty around the pace of adoption and the timing of potential commercial revenue.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.82 and its highest was $12.00 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.82B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Nov 04, 2026 which is in 12 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Aug 05, 2026. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.333 by $0.137.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.74.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 169,215,960 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of $0.47 in its last earnings report, beating expectations of $0.333. Following the earnings report the stock price went down -3.787%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.29 (92.11% Upside)
$21.29 (92.11% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 476.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.58%
12-Months-Change
Fundamentals
Return on Equity
-29.99%
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong clinical and commercial progress (notably robust SOLSTICE Week 96 efficacy, completion of registrational enrollment for ECLIPSE, manufacturing milestones for drug substance, a strengthened balance sheet with ~ $1.01B cash and substantive Astellas funding, and accelerated oncology development with VIR-5500 expansion cohorts). Offsetting risks include higher R&D and SG&A driven by milestone and one-time items, reliance on collaboration revenue for near-term profitability, low current HDV diagnosis rates that could limit short-term market uptake, remaining CMC/drug product activities, and ongoing C-suite hiring. On balance, the positives (clinical data, enrollment completion, cash runway, strategic partnerships and oncology momentum) materially outweigh the near-term operational and market risks.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$21.29
▲(92.11% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
13.82% Mutual Funds
0.02% Other Institutional Investors
51.11% Public Companies and Individual Investors